FDA milestone vests shares for Travere Therapeutics (NASDAQ: TVTX) CRO

Rhea-AI Filing Summary

Travere Therapeutics Chief Research Officer William E. Rote reported receiving 14,000 shares of common stock as an equity award. The shares were acquired at no cost and are tied to performance restricted stock units granted on January 31, 2025.

According to the disclosure, these PSUs vested on April 13, 2026 after Travere confirmed that the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS. Following this vesting and share issuance, Rote directly holds 123,087 shares of Travere Therapeutics common stock, reflecting both this award and his existing stake.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider ROTE WILLIAM E.

Role Chief Research Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,000	$0.00	--

Holdings After Transaction: Common Stock — 123,087 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares awarded: 14,000 shares Price per share: $0.00 per share Shares held after: 123,087 shares +3 more

6 metrics

Shares awarded 14,000 shares Common stock received as PSU award on April 13, 2026

Price per share $0.00 per share Grant/award acquisition of common stock

Shares held after 123,087 shares Direct ownership following the April 13, 2026 award

FDA approval trigger FILSPARI approved in FSGS PSUs vested upon FDA approval as confirmed by issuer

PSU grant date January 31, 2025 Date performance restricted stock units were originally granted

PSU vesting date April 13, 2026 Date PSUs vested and shares were delivered

Key Terms

performance restricted stock units (PSUs), U.S. Food and Drug Administration (FDA), FILSPARI (sparsentan), FSGS, +1 more

5 terms

performance restricted stock units (PSUs) financial

"the reporting person was granted performance restricted stock units (PSUs) which PSUs vested"

U.S. Food and Drug Administration (FDA) regulatory

"upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

FILSPARI (sparsentan) medical

"FDA had granted approval of FILSPARI (sparsentan) in FSGS"

FSGS medical

"FDA had granted approval of FILSPARI (sparsentan) in FSGS"

Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which small sections of the organ’s filtering units become scarred, lowering their ability to remove waste and manage fluids. Investors care because drug candidates, diagnostics, or clinical trial results addressing FSGS can meaningfully affect a biotech or pharmaceutical company’s revenue prospects and regulatory outlook—like fixing a specific engine fault that can restore performance and change a vehicle’s value.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTE WILLIAM E.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/13/2026		A(1)		14,000	A	$0	123,087	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Travere Therapeutics (TVTX) report for William E. Rote?

Travere Therapeutics reported that Chief Research Officer William E. Rote acquired 14,000 shares of common stock as a performance-based equity award. The shares were issued at no cost upon vesting of previously granted PSUs, increasing his direct holdings to 123,087 shares.

How many Travere Therapeutics (TVTX) shares does William E. Rote now hold?

After the reported transaction, Chief Research Officer William E. Rote directly holds 123,087 shares of Travere Therapeutics common stock. This total includes the 14,000 shares received from vested performance restricted stock units, reflecting his updated equity stake in the company.

What triggered the vesting of William E. Rote’s PSUs at Travere Therapeutics (TVTX)?

The PSUs vested when Travere confirmed that the FDA approved FILSPARI (sparsentan) in FSGS. These performance restricted stock units were originally granted on January 31, 2025 and vested on April 13, 2026 once this regulatory milestone was achieved.

Were William E. Rote’s newly acquired Travere Therapeutics (TVTX) shares purchased on the market?

No, the 14,000 Travere Therapeutics shares were awarded as compensation, not bought in the open market. They were issued at a price of $0.00 per share upon vesting of performance restricted stock units tied to an FDA approval milestone.

What role does William E. Rote hold at Travere Therapeutics (TVTX) in this Form 4 filing?

In this Form 4, William E. Rote is identified as Chief Research Officer of Travere Therapeutics. The filing shows a performance-based stock award that increased his direct ownership to 123,087 common shares, aligning his compensation with a key regulatory milestone achievement.